Wide Ranks

LLY

Eli Lilly and Company

788.19

Top Statistics
Market Cap 708 B Forward PE 34.88 Revenue Growth 20.40 %
Current Ratio 1.27 Trailing PE 84.75 Earnings Growth 0.00 %
Profit Margins 20.48 % Peg Ratio Dividend Yield 0.66 %
Enterprice / EBITA 44.47 Enterprise / Revenue 18.03 Price To Sales Trailing12 Months 17.35
Profitability
Profit Margins 20.48 % Operating Margins 39.77 %
Balance Sheet
Total Cash 3 B Total Cash Per Share 3.91 Total Debt 31 B
Total Debt To Equity 218.08 Current Ratio 1.27 Book Value Per Share 15.82
All Measures
Short Ratio 154.00 % Message Board Id finmb_285467 Shares Short Prior Month 5 M
Return On Equity 0.6532 City Indianapolis Uuid 7b37be39-dfde-3602-b0e4-4d76cf52143b
Previous Close 789.32 First Trade Date Epoch Utc 76 M Book Value 15.82
Beta 0.4300 Total Debt 31 B Volume 2 M
Price To Book 49.81 Last Split Date 876 M Fifty Two Week Low 561.65
Total Cash Per Share 3.91 Total Revenue 40 B Shares Short Previous Month Date 1 B
Target Median Price 1005.00 Max Age 86400 Recommendation Mean 1.71
Sand P52 Week Change 0.3133 Operating Margins 39.77 % Last Dividend Value 1.30
Target Mean Price 992.18 Net Income To Common 8 B Ask 790.00
Short Percent Of Float 0.0082 Implied Shares Outstanding 899 M Last Fiscal Year End 1 B
Trailing Peg Ratio 74.07 % Average Daily Volume10 Day 5 M Average Volume10days 5 M
Total Cash 3 B Next Fiscal Year End 1 B Revenue Per Share 45.37
Held Percent Insiders 0.0015 Ebitda Margins 40.54 % Dividend Rate 5.20
Trailing PE 84.75 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 789.32 Target Low Price 580.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 856.91 Open 788.12 Dividend Yield 0.66 %
State IN Free Cashflow -1306887552 Return On Assets 0.1395
Time Zone Short Name EST Trailing Eps 9.30 Day Low 780.30
Address1 Lilly Corporate Center Trailing Annual Dividend Rate 5.03 Price Hint 2
Shares Outstanding 899 M Target High Price 1250.00 Website https://www.lilly.com
52 Week Change 0.3336 Average Volume 3 M Forward Eps 22.66
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 63.00 %
Last Split Factor 2:1 Regular Market Day High 794.83 Is_sp_500 True
Profit Margins 20.48 % Debt To Equity 218.08 Fifty Two Week High 972.53
Day High 794.83 Shares Short 6 M Regular Market Open 788.12
Industry Key drug-manufacturers-general Bid 785.00 Earnings Growth 0.00 %
Enterprise To Revenue 18.03 Revenue Growth 20.40 % Shares Percent Shares Out 0.0073
Operating Cashflow 6 B Five Year Avg Dividend Yield 126.00 % Currency USD
Market Cap 708 B Time Zone Full Name America/New_York Is_nasdaq_100 False
Zip 46285 Payout Ratio 54.20 % Quote Type EQUITY
Industry Drug Manufacturers - General Ex Dividend Date 1 B Regular Market Day Low 780.30
Held Percent Institutions 0.8338 Long Name Eli Lilly and Company Current Price 788.19
Enterprise To Ebitda 44.47 Financial Currency USD Trailing Annual Dividend Yield 0.64 %
Current Ratio 1.27 Gross Margins 80.91 % Industry Disp Drug Manufacturers - General
Number Of Analyst Opinions 28 Country United States Float Shares 897 M
Two Hundred Day Average 836.39 Ir Website http://investor.lilly.com/ Enterprise Value 736 B
Price To Sales Trailing12 Months 17.35 Forward PE 34.88 Regular Market Volume 2 M
Last Dividend Date 1 B Ebitda 16 B Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.

In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache.

Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.

It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain.

It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F.

Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co.

, Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes.

The company was founded in 1876 and is headquartered in Indianapolis, Indiana.